BLUMONT GROUP LTD

(Company Registration No. 199302554G)
(Incorporated in the Republic of Singapore)
("Company" and together with its subsidiaries, the "Group")

RESPONSE TO QUERIES RAISED BY SGX REGCO

The board of directors ("Board" or "Directors") of the Company refers to the queries raised by the Singapore Exchange Regulation ("SGX RegCo") on 11 March 2021 in relation to the Company's full year results for the financial year ended 31 December 2020 ("Full Year Results") and wishes to provide the Company's responses to the queries raised as follows:

Question Response The Company had inadvertently left an editorial omission in Paragraph 1. The decrease in revenue was attributed mainly to decreased 13 of the Full Year Results and had meant for the sentence to continue sterilisation services rendered. to say that the decrease in performance of the sterilisation segment of the Group during the reporting period due to the impact of COVID-19 Please reconcile this information was consistent with the severely affected financial performance of many with information disclosed in industries worldwide as a result of COVID-19. This will be rectified and Paragraph 13, which provides that the performance of the stated in completeness in the Company's Annual Report 2020. sterilisation segment of the Group has been consistent. Please provide a breakdown of The breakdown of trade and other payables as at 31 December 2020 trade and other payables of and 31 December 2019 are as follows: S\$1,548,000 and S\$1,682,000 as at 31 December 2020 and 31 December 2019 respectively. 2019 2020 Trade and Other Payables Other payables 624,424.00 765,559.00 Accrued operating expenses 243,909.00 229,656.00 Amounts due to directors \$ 50,000.00 \$ 5,225.00 Deposit payable \$ 164,700.00 362,120.00 Interest payables 464,974.00 \$ 319,606.00 Total trade and other payables \$1,548,007.00 \$1,682,166.00

3. As at 31 December 2020, the Group recorded negative working capital of \$\$331,000 with cash and bank balances of \$\$917,000. Please disclose the pro-active actions which management has taken and/or plans to take to ensure that the Group's financial position remains strong.

The Group has implemented various cost containing measures to generate savings and conserve financial resources such as cost reductions.

The Board and the management are currently exploring possible fundraising options to secure financing commitments to allow the Group to have access to additional working capital where required. In addition, the Board and the management are always looking out for potential corporate actions such as those relating to new business opportunities or monetising its assets to generate working capital for the Group. The Company will make the relevant announcements as and when it implements such plans.

Barring any unforeseen circumstances, with the start of the global recovery from the COVID-19 pandemic, the Group expects its financial position to strengthen with the recovering revenue stream of its sterilisation business.

It is noted that the cash and bank balance of the Company is approximately \$\$917,000. Management has assessed the cash flow forecasts of the Group for the next 12 months and concluded that there will be sufficient cash flows and resources to allow the Group to continue its operations and meet its obligations for the foreseeable future.

The Board has assessed the ability of the Group to meet its short-term obligations as and when it falls due and is also of the opinion that the

		Group will be able to raise the necessary funds for its working capital purposes when required.
asses ability conce	e provide the Board's sment of the Company's to operate as a going ern, and the bases for such sessment.	
asses ability obliga due, a	e provide the Board's sment of the Company's to meet its short-term tions as and when they fall and the bases for such an sment.	·

BY ORDER OF THE BOARD

John Lee Yow Meng Executive Director and Chief Financial Officer 15 March 2021